سوق علاج الصدفية العالمي - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL PSORIASIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL PSORIASIS TREATMENT MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL PSORIASIS TREATMENT MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER'S 5 FORCES

4.2 PESTEL ANALYSIS

 

5 EPIDEMIOLOGY

5.1 INCIDENCE OF ALL BY GENDER

5.2 TREATMENT RATE

5.3 MORTALITY RATE

5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

5.5 PATEINT TREATMENT SUCCESS RATES

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

6.7 INTERVIEWS WITH DERMATOLOGIST

6.8 OTHER KOL SNAPSHOTS

7 REGULATORY SCENARIO

7.1 FDA APPROVALS

7.2 EMA APPROVALS

8 MERGERS AND ACQUISITION

8.1 LICENSING

8.2 COMMERCIALIZATION AGREEMENTS

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.4 PHASE II CANDIDATES

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

10 MARKET OVERVIEW

10.1 DRIVERS

10.2 RESTRAINS

10.3 OPPURTUNITY

10.4 CHALLENGES

 

11 GLOBAL PSORIASIS TREATMENT MARKET, BY DISEASE TYPE

11.1 OVERVIEW

11.2 PLAQUE PSORIASIS, BY TREATMENT

11.2.1 MEDICATION

11.2.1.1. CORTICOSTEROIDS

11.2.1.1.1. HYDROCORTISONE, BY BRAND

11.2.1.1.1.1 HYDROCORT

11.2.1.1.1.1.1. MARKET VALUE (USD MN)

A. MARKET VOLUME (IU)

B. AVERAGE SELLING PRICE (USD)

11.2.1.1.1.2 ALPHOSYL

11.2.1.1.1.2.1. MARKET VALUE (USD MN)

11.2.1.1.1.2.2. MARKET VOLUME (IU)

11.2.1.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.1.3 AQUACORT

11.2.1.1.1.3.1. MARKET VALUE (USD MN)

11.2.1.1.1.3.2. MARKET VOLUME (IU)

11.2.1.1.1.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.1.4 OTHERS

11.2.1.1.2. TRIAMCINOLONE, BY BRAND

11.2.1.1.2.1 KENALOG IV

11.2.1.1.2.1.1. MARKET VALUE (USD MN)

11.2.1.1.2.1.2. MARKET VOLUME (IU)

11.2.1.1.2.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.2.2 ARISTOSPAN

11.2.1.1.2.2.1. MARKET VALUE (USD MN)

11.2.1.1.2.2.2. MARKET VOLUME (IU)

11.2.1.1.2.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.2.3 TRIVARIS

11.2.1.1.2.3.1. MARKET VALUE (USD MN)

11.2.1.1.2.3.2. MARKET VOLUME (IU)

11.2.1.1.2.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.2.4 OTHERS

 

11.2.1.1.3. CLOBETASOL, BY BRAND

11.2.1.1.3.1 TEMOVATE

11.2.1.1.3.1.1. MARKET VALUE (USD MN)

11.2.1.1.3.1.2. MARKET VOLUME (IU)

11.2.1.1.3.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.3.2 CLOBEX

11.2.1.1.3.2.1. MARKET VALUE (USD MN)

11.2.1.1.3.2.2. MARKET VOLUME (IU)

11.2.1.1.3.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.3.3 OLUX

11.2.1.1.3.3.1. MARKET VALUE (USD MN)

11.2.1.1.3.3.2. MARKET VOLUME (IU)

11.2.1.1.3.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.3.4 OTHERS

11.2.1.2. CALCINEURIN INHIBITORS

11.2.1.2.1. TACROLIMUS, BY BRAND

11.2.1.2.1.1 PROGRAF

11.2.1.2.1.1.1. MARKET VALUE (USD MN)

11.2.1.2.1.1.2. MARKET VOLUME (IU)

11.2.1.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.2.1.2 ENVARSUS XR

11.2.1.2.1.2.1. MARKET VALUE (USD MN)

11.2.1.2.1.2.2. MARKET VOLUME (IU)

11.2.1.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.2.1.3 ASTAGRAF XL

11.2.1.2.1.3.1. MARKET VALUE (USD MN)

11.2.1.2.1.3.2. MARKET VOLUME (IU)

11.2.1.2.1.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.2.1.4 OTHERS

11.2.1.2.2. PIMECROLIMUS (ELIDEL)

11.2.1.2.2.1.1. MARKET VALUE (USD MN)

11.2.1.2.2.1.2. MARKET VOLUME (IU)

11.2.1.2.2.1.3. AVERAGE SELLING PRICE (USD)

 

11.2.1.3. IMMUNOSUPPRESSANT

11.2.1.3.1. CYCLOSPORINE, BY BRAND NAME

11.2.1.3.1.1 SANDMMUNE

11.2.1.3.1.1.1. MARKET VALUE (USD MN)

11.2.1.3.1.1.2. MARKET VOLUME (IU)

11.2.1.3.1.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.3.1.2 NEORAL

11.2.1.3.1.2.1. MARKET VALUE (USD MN)

11.2.1.3.1.2.2. MARKET VOLUME (IU)

11.2.1.3.1.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.3.1.3 RESTASIS

11.2.1.3.1.3.1. MARKET VALUE (USD MN)

11.2.1.3.1.3.2. MARKET VOLUME (IU)

11.2.1.3.1.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.3.1.4 OTHERS

11.2.1.3.2. METHOTREXATE, BY BRAND NAME

11.2.1.3.2.1 TREXALL

11.2.1.3.2.1.1. MARKET VALUE (USD MN)

11.2.1.3.2.1.2. MARKET VOLUME (IU)

11.2.1.3.2.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.3.2.2 OTREXUP

11.2.1.3.2.2.1. MARKET VALUE (USD MN)

11.2.1.3.2.2.2. MARKET VOLUME (IU)

11.2.1.3.2.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.3.2.3 RASUVO

11.2.1.3.2.3.1. MARKET VALUE (USD MN)

11.2.1.3.2.3.2. MARKET VOLUME (IU)

11.2.1.3.2.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.3.2.4 OTHERS

11.2.1.3.3. BIOLOGIC DRUGS

11.2.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS

11.2.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

 

11.2.1.3.3.1.2. ETANERCEPT, BY BRAND NAME

A. ENBREL

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. ERELZI

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTHERS

11.2.1.3.3.1.3. ADALIMUMAB, BY BRAND

A. HUMIRA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. AMGEVITA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. HYRIMOZ

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

D. OTHERS

11.2.1.3.3.1.4. INFLIXIMAB, BY BRAND

A. REMICADE

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. RENFLEXIS

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTERS

 

11.2.1.3.3.1.5. GOLIMUMAB, (SIMPONI)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.2.1.3.3.1.6. OTHERS

11.2.1.3.3.2 INTERLEUKIN

11.2.1.3.3.2.1. USTEKINUMAB (STELARA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

11.2.1.3.3.2.2. AVERAGE SELLING PRICE (USD SECUKINUMAB (COSENTYX)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.2.1.3.3.2.3. GUSELKUMAB (TREMFYA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.2.1.3.3.2.4. OTHERS

11.2.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.2.1.3.4. OTHERS

11.2.2 TOPICAL THERAPY

11.2.2.1. VITAMIN D

11.2.2.1.1. CALCIPOTRIENE,BY BRAND

11.2.2.1.1.1 DOVONEX

11.2.2.1.1.1.1. MARKET VALUE (USD MN)

11.2.2.1.1.1.2. MARKET VOLUME (IU)

11.2.2.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.2.2.1.1.2 SORILUX

11.2.2.1.1.2.1. MARKET VALUE (USD MN)

11.2.2.1.1.2.2. MARKET VOLUME (IU)

11.2.2.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.2.2.1.1.3 OTHERS

 

11.2.2.1.2. CALCITRIOL (VECTICAL)

11.2.2.1.2.1 MARKET VALUE (USD MN)

11.2.2.1.2.2 MARKET VOLUME (IU)

11.2.2.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.2.2. RETINOIDS (TAZAROTENE), BY BRAND

11.2.2.2.1. TAZORAC

11.2.2.2.1.1 MARKET VALUE (USD MN)

11.2.2.2.1.2 MARKET VOLUME (IU)

11.2.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.2.2.2.2. AVAGE

11.2.2.2.2.1 MARKET VALUE (USD MN)

11.2.2.2.2.2 MARKET VOLUME (IU)

11.2.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.2.2.2.3. OTHERS

11.2.2.3. ANTHRALIN

11.2.2.3.1. MARKET VALUE (USD MN)

11.2.2.3.2. MARKET VOLUME (IU)

11.2.2.3.3. AVERAGE SELLING PRICE (USD)

11.2.2.4. SALICYLIC ACID

11.2.2.4.1. MARKET VALUE (USD MN)

11.2.2.4.2. MARKET VOLUME (IU)

11.2.2.4.3. AVERAGE SELLING PRICE (USD)

11.2.2.5. COAL TAR

11.2.2.5.1. MARKET VALUE (USD MN)

11.2.2.5.2. MARKET VOLUME (IU)

11.2.2.5.3. AVERAGE SELLING PRICE (USD)

11.2.2.6. OTHERS

11.2.3 LIGHT THERAPY

11.2.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)

11.2.3.2. UV B

11.2.3.2.1. BROAD BAND

11.2.3.2.2. NARROW BAND

11.2.3.3. EXCIMER LASER

11.2.4 SYMPTOMATIC MEDICINE

11.2.4.1. ALOE EXTRACT CREAM

11.2.4.1.1. MARKET VALUE (USD MN)

11.2.4.1.2. MARKET VOLUME (IU)

11.2.4.1.3. AVERAGE SELLING PRICE (USD)

 

11.2.4.2. FISH OIL SUPPLEMENTS

11.2.4.2.1. MARKET VALUE (USD MN)

11.2.4.2.2. MARKET VOLUME (IU)

11.2.4.2.3. AVERAGE SELLING PRICE (USD)

11.2.4.3. OREGON GRAPE

11.2.4.3.1. MARKET VALUE (USD MN)

11.2.4.3.2. MARKET VOLUME (IU)

11.2.4.3.3. AVERAGE SELLING PRICE (USD)

11.3 GUTTATE PSORIASIS

11.3.1 MEDICATION

11.3.1.1. CORTICOSTEROIDS

11.3.1.1.1. HYDROCORTISONE, BY BRAND

11.3.1.1.1.1 HYDROCORT

11.3.1.1.1.1.1. MARKET VALUE (USD MN)

11.3.1.1.1.1.2. MARKET VOLUME (IU)

11.3.1.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.1.2 ALPHOSYL

11.3.1.1.1.2.1. MARKET VALUE (USD MN)

11.3.1.1.1.2.2. MARKET VOLUME (IU)

11.3.1.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.1.3 AQUACORT

11.3.1.1.1.3.1. MARKET VALUE (USD MN)

11.3.1.1.1.3.2. MARKET VOLUME (IU)

11.3.1.1.1.3.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.1.4 OTHERS

11.3.1.1.2. TRIAMCINOLONE, BY BRAND

11.3.1.1.2.1 KENALOG IV

11.3.1.1.2.1.1. MARKET VALUE (USD MN)

11.3.1.1.2.1.2. MARKET VOLUME (IU)

11.3.1.1.2.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.2.2 ARISTOSPAN

11.3.1.1.2.2.1. MARKET VALUE (USD MN)

11.3.1.1.2.2.2. MARKET VOLUME (IU)

11.3.1.1.2.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.2.3 TRIVARIS

11.3.1.1.2.3.1. MARKET VALUE (USD MN)

11.3.1.1.2.3.2. MARKET VOLUME (IU)

11.3.1.1.2.3.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.2.4 OTHERS

11.3.1.1.3. CLOBETASOL, BY BRAND

11.3.1.1.3.1 TEMOVATE

11.3.1.1.3.1.1. MARKET VALUE (USD MN)

11.3.1.1.3.1.2. MARKET VOLUME (IU)

11.3.1.1.3.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.3.2 CLOBEX

11.3.1.1.3.2.1. MARKET VALUE (USD MN)

11.3.1.1.3.2.2. MARKET VOLUME (IU)

11.3.1.1.3.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.3.3 OLUX

11.3.1.1.3.3.1. MARKET VALUE (USD MN)

11.3.1.1.3.3.2. MARKET VOLUME (IU)

11.3.1.1.3.3.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.3.4 OTHERS

11.3.1.2. CALCINEURIN INHIBITORS

11.3.1.2.1. TACROLIMUS, BY BRAND

11.3.1.2.1.1 PROGRAF

11.3.1.2.1.1.1. MARKET VALUE (USD MN)

11.3.1.2.1.1.2. MARKET VOLUME (IU)

11.3.1.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.2.1.2 ENVARSUS XR

11.3.1.2.1.2.1. MARKET VALUE (USD MN)

11.3.1.2.1.2.2. MARKET VOLUME (IU)

11.3.1.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.2.1.3 ASTAGRAF XL

11.3.1.2.1.3.1. MARKET VALUE (USD MN)

11.3.1.2.1.3.2. MARKET VOLUME (IU)

11.3.1.2.1.3.3. AVERAGE SELLING PRICE (USD)

11.3.1.2.1.4 OTHERS

11.3.1.2.2. PIMECROLIMUS (ELIDEL)

11.3.1.2.2.1.1. MARKET VALUE (USD MN)

11.3.1.2.2.1.2. MARKET VOLUME (IU)

11.3.1.2.2.1.3. AVERAGE SELLING PRICE (USD)

 

11.3.1.3. IMMUNOSUPPRESSANT

11.3.1.3.1. CYCLOSPORINE, BY BRAND NAME

11.3.1.3.1.1 SANDMMUNE

11.3.1.3.1.1.1. MARKET VALUE (USD MN)

11.3.1.3.1.1.2. MARKET VOLUME (IU)

11.3.1.3.1.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.3.1.2 NEORAL

11.3.1.3.1.2.1. MARKET VALUE (USD MN)

11.3.1.3.1.2.2. MARKET VOLUME (IU)

11.3.1.3.1.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.3.1.3 RESTASIS

11.3.1.3.1.3.1. MARKET VALUE (USD MN)

11.3.1.3.1.3.2. MARKET VOLUME (IU)

11.3.1.3.1.3.3. AVERAGE SELLING PRICE (USD)

11.3.1.3.1.4 OTHERS

11.3.1.3.2. METHOTREXATE, BY BRAND NAME

11.3.1.3.2.1 TREXALL

11.3.1.3.2.1.1. MARKET VALUE (USD MN)

11.3.1.3.2.1.2. MARKET VOLUME (IU)

11.3.1.3.2.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.3.2.2 OTREXUP

11.3.1.3.2.2.1. MARKET VALUE (USD MN)

11.3.1.3.2.2.2. MARKET VOLUME (IU)

11.3.1.3.2.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.3.2.3 RASUVO

11.3.1.3.2.3.1. MARKET VALUE (USD MN)

11.3.1.3.2.3.2. MARKET VOLUME (IU)

11.3.1.3.2.3.3. AVERAGE SELLING PRICE (USD)

11.3.1.3.2.4 OTHERS

11.3.1.3.3. BIOLOGIC DRUGS

11.3.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS

11.3.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

 

11.3.1.3.3.1.2. ETANERCEPT, BY BRAND NAME

A. ENBREL

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. ERELZI

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTHERS

11.3.1.3.3.1.3. ADALIMUMAB, BY BRAND

A. HUMIRA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. AMGEVITA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. HYRIMOZ

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

D. OTHERS

11.3.1.3.3.1.4. INFLIXIMAB, BY BRAND

A. REMICADE

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. RENFLEXIS

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTERS

 

11.3.1.3.3.1.5. GOLIMUMAB, (SIMPONI)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.3.1.3.3.1.6. OTHERS

11.3.1.3.3.2 INTERLEUKIN

11.3.1.3.3.2.1. USTEKINUMAB (STELARA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.3.1.3.3.2.2. SECUKINUMAB (COSENTYX)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.3.1.3.3.2.3. GUSELKUMAB (TREMFYA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.3.1.3.3.2.4. OTHERS

11.3.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.3.1.3.4. OTHERS

11.3.2 TOPICAL THERAPY

11.3.2.1. VITAMIN D

11.3.2.1.1. CALCIPOTRIENE,BY BRAND

11.3.2.1.1.1 DOVONEX

11.3.2.1.1.1.1. MARKET VALUE (USD MN)

11.3.2.1.1.1.2. MARKET VOLUME (IU)

11.3.2.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.3.2.1.1.2 SORILUX

11.3.2.1.1.2.1. MARKET VALUE (USD MN)

11.3.2.1.1.2.2. MARKET VOLUME (IU)

11.3.2.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.3.2.1.1.3 OTHERS

 

11.3.2.1.2. CALCITRIOL (VECTICAL)

11.3.2.1.2.1 MARKET VALUE (USD MN)

11.3.2.1.2.2 MARKET VOLUME (IU)

11.3.2.1.2.3 AVERAGE SELLING PRICE (USD)

11.3.2.2. RETINOIDS (TAZAROTENE), BY BRAND

11.3.2.2.1. TAZORAC

11.3.2.2.1.1 MARKET VALUE (USD MN)

11.3.2.2.1.2 MARKET VOLUME (IU)

11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.3.2.2.2. AVAGE

11.3.2.2.2.1 MARKET VALUE (USD MN)

11.3.2.2.2.2 MARKET VOLUME (IU)

11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.3.2.2.3. OTHERS

11.3.2.3. ANTHRALIN

11.3.2.3.1. MARKET VALUE (USD MN)

11.3.2.3.2. MARKET VOLUME (IU)

11.3.2.3.3. AVERAGE SELLING PRICE (USD)

11.3.2.4. SALICYLIC ACID

11.3.2.4.1. MARKET VALUE (USD MN)

11.3.2.4.2. MARKET VOLUME (IU)

11.3.2.4.3. AVERAGE SELLING PRICE (USD)

11.3.2.5. COAL TAR

11.3.2.5.1. MARKET VALUE (USD MN)

11.3.2.5.2. MARKET VOLUME (IU)

11.3.2.5.3. AVERAGE SELLING PRICE (USD)

11.3.2.6. OTHERS

11.3.3 LIGHT THERAPY

11.3.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)

11.3.3.2. UV B

11.3.3.2.1. BROAD BAND

11.3.3.2.2. NARROW BAND

11.3.3.3. EXCIMER LASER

11.3.4 SYMPTOMATIC MEDICINE

11.3.4.1. ALOE EXTRACT CREAM

11.3.4.1.1. MARKET VALUE (USD MN)

11.3.4.1.2. MARKET VOLUME (IU)

11.3.4.1.3. AVERAGE SELLING PRICE (USD)

 

11.3.4.2. FISH OIL SUPPLEMENTS

11.3.4.2.1. MARKET VALUE (USD MN)

11.3.4.2.2. MARKET VOLUME (IU)

11.3.4.2.3. AVERAGE SELLING PRICE (USD)

11.3.4.3. OREGON GRAPE

11.3.4.3.1. MARKET VALUE (USD MN)

11.3.4.3.2. MARKET VOLUME (IU)

11.3.4.3.3. AVERAGE SELLING PRICE (USD)

11.4 INVERSE PSORIASIS

11.4.1 MEDICATION

11.4.1.1. CORTICOSTEROIDS

11.4.1.1.1. HYDROCORTISONE, BY BRAND

11.4.1.1.1.1 HYDROCORT

11.4.1.1.1.1.1. MARKET VALUE (USD MN)

11.4.1.1.1.1.2. MARKET VOLUME (IU)

11.4.1.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.1.2 ALPHOSYL

11.4.1.1.1.2.1. MARKET VALUE (USD MN)

11.4.1.1.1.2.2. MARKET VOLUME (IU)

11.4.1.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.1.3 AQUACORT

11.4.1.1.1.3.1. MARKET VALUE (USD MN)

11.4.1.1.1.3.2. MARKET VOLUME (IU)

11.4.1.1.1.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.1.4 OTHERS

11.4.1.1.2. TRIAMCINOLONE, BY BRAND

11.4.1.1.2.1 KENALOG IV

11.4.1.1.2.1.1. MARKET VALUE (USD MN)

11.4.1.1.2.1.2. MARKET VOLUME (IU)

11.4.1.1.2.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.2.2 ARISTOSPAN

11.4.1.1.2.2.1. MARKET VALUE (USD MN)

11.4.1.1.2.2.2. MARKET VOLUME (IU)

11.4.1.1.2.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.2.3 TRIVARIS

11.4.1.1.2.3.1. MARKET VALUE (USD MN)

11.4.1.1.2.3.2. MARKET VOLUME (IU)

11.4.1.1.2.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.2.4 OTHERS

11.4.1.1.3. CLOBETASOL, BY BRAND

11.4.1.1.3.1 TEMOVATE

11.4.1.1.3.1.1. MARKET VALUE (USD MN)

11.4.1.1.3.1.2. MARKET VOLUME (IU)

11.4.1.1.3.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.3.2 CLOBEX

11.4.1.1.3.2.1. MARKET VALUE (USD MN)

11.4.1.1.3.2.2. MARKET VOLUME (IU)

11.4.1.1.3.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.3.3 OLUX

11.4.1.1.3.3.1. MARKET VALUE (USD MN)

11.4.1.1.3.3.2. MARKET VOLUME (IU)

11.4.1.1.3.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.3.4 OTHERS

11.4.1.2. CALCINEURIN INHIBITORS

11.4.1.2.1. TACROLIMUS, BY BRAND

11.4.1.2.1.1 PROGRAF

11.4.1.2.1.1.1. MARKET VALUE (USD MN)

11.4.1.2.1.1.2. MARKET VOLUME (IU)

11.4.1.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.2.1.2 ENVARSUS XR

11.4.1.2.1.2.1. MARKET VALUE (USD MN)

11.4.1.2.1.2.2. MARKET VOLUME (IU)

11.4.1.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.2.1.3 ASTAGRAF XL

11.4.1.2.1.3.1. MARKET VALUE (USD MN)

11.4.1.2.1.3.2. MARKET VOLUME (IU)

11.4.1.2.1.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.2.1.4 OTHERS

11.4.1.2.2. PIMECROLIMUS (ELIDEL)

11.4.1.2.2.1.1. MARKET VALUE (USD MN)

11.4.1.2.2.1.2. MARKET VOLUME (IU)

11.4.1.2.2.1.3. AVERAGE SELLING PRICE (USD)

 

11.4.1.3. IMMUNOSUPPRESSANT

11.4.1.3.1. CYCLOSPORINE, BY BRAND NAME

11.4.1.3.1.1 SANDMMUNE

11.4.1.3.1.1.1. MARKET VALUE (USD MN)

11.4.1.3.1.1.2. MARKET VOLUME (IU)

11.4.1.3.1.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.3.1.2 NEORAL

11.4.1.3.1.2.1. MARKET VALUE (USD MN)

11.4.1.3.1.2.2. MARKET VOLUME (IU)

11.4.1.3.1.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.3.1.3 RESTASIS

11.4.1.3.1.3.1. MARKET VALUE (USD MN)

11.4.1.3.1.3.2. MARKET VOLUME (IU)

11.4.1.3.1.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.3.1.4 OTHERS

11.4.1.3.2. METHOTREXATE, BY BRAND NAME

11.4.1.3.2.1 TREXALL

11.4.1.3.2.1.1. MARKET VALUE (USD MN)

11.4.1.3.2.1.2. MARKET VOLUME (IU)

11.4.1.3.2.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.3.2.2 OTREXUP

11.4.1.3.2.2.1. MARKET VALUE (USD MN)

11.4.1.3.2.2.2. MARKET VOLUME (IU)

11.4.1.3.2.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.3.2.3 RASUVO

11.4.1.3.2.3.1. MARKET VALUE (USD MN)

11.4.1.3.2.3.2. MARKET VOLUME (IU)

11.4.1.3.2.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.3.2.4 OTHERS

11.4.1.3.3. BIOLOGIC DRUGS

11.4.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS

11.4.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

 

11.4.1.3.3.1.2. ETANERCEPT, BY BRAND NAME

A. ENBREL

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. ERELZI

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTHERS

11.4.1.3.3.1.3. ADALIMUMAB, BY BRAND

A. HUMIRA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. AMGEVITA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. HYRIMOZ

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

D. OTHERS

11.4.1.3.3.1.4. INFLIXIMAB, BY BRAND

A. REMICADE

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. RENFLEXIS

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTERS

11.4.1.3.3.1.5. GOLIMUMAB, (SIMPONI)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.4.1.3.3.1.6. OTHERS

11.4.1.3.3.2 INTERLEUKIN

11.4.1.3.3.2.1. USTEKINUMAB (STELARA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.4.1.3.3.2.2. SECUKINUMAB (COSENTYX)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.4.1.3.3.2.3. GUSELKUMAB (TREMFYA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.4.1.3.3.2.4. OTHERS

11.4.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.4.1.3.4. OTHERS

11.4.2 TOPICAL THERAPY

11.4.2.1. VITAMIN D

11.4.2.1.1. CALCIPOTRIENE,BY BRAND

11.4.2.1.1.1 DOVONEX

11.4.2.1.1.1.1. MARKET VALUE (USD MN)

11.4.2.1.1.1.2. MARKET VOLUME (IU)

11.4.2.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.4.2.1.1.2 SORILUX

11.4.2.1.1.2.1. MARKET VALUE (USD MN)

11.4.2.1.1.2.2. MARKET VOLUME (IU)

11.4.2.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.4.2.1.1.3 OTHERS

11.4.2.1.2. CALCITRIOL (VECTICAL)

11.4.2.1.2.1 MARKET VALUE (USD MN)

11.4.2.1.2.2 MARKET VOLUME (IU)

11.4.2.1.2.3 AVERAGE SELLING PRICE (USD)

 

11.4.2.2. RETINOIDS (TAZAROTENE), BY BRAND

11.4.2.2.1. TAZORAC

11.4.2.2.1.1 MARKET VALUE (USD MN)

11.4.2.2.1.2 MARKET VOLUME (IU)

11.4.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.4.2.2.2. AVAGE

11.4.2.2.2.1 MARKET VALUE (USD MN)

11.4.2.2.2.2 MARKET VOLUME (IU)

11.4.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.4.2.2.3. OTHERS

11.4.2.3. ANTHRALIN

11.4.2.3.1. MARKET VALUE (USD MN)

11.4.2.3.2. MARKET VOLUME (IU)

11.4.2.3.3. AVERAGE SELLING PRICE (USD)

11.4.2.4. SALICYLIC ACID

11.4.2.4.1. MARKET VALUE (USD MN)

11.4.2.4.2. MARKET VOLUME (IU)

11.4.2.4.3. AVERAGE SELLING PRICE (USD)

11.4.2.5. COAL TAR

11.4.2.5.1. MARKET VALUE (USD MN)

11.4.2.5.2. MARKET VOLUME (IU)

11.4.2.5.3. AVERAGE SELLING PRICE (USD)

11.4.2.6. OTHERS

11.4.3 LIGHT THERAPY

11.4.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)

11.4.3.2. UV B

11.4.3.2.1. BROAD BAND

11.4.3.2.2. NARROW BAND

11.4.3.3. EXCIMER LASER

11.4.4 SYMPTOMATIC MEDICINE

11.4.4.1. ALOE EXTRACT CREAM

11.4.4.1.1. MARKET VALUE (USD MN)

11.4.4.1.2. MARKET VOLUME (IU)

11.4.4.1.3. AVERAGE SELLING PRICE (USD)

11.4.4.2. FISH OIL SUPPLEMENTS

11.4.4.2.1. MARKET VALUE (USD MN)

11.4.4.2.2. MARKET VOLUME (IU)

11.4.4.2.3. AVERAGE SELLING PRICE (USD)

 

11.4.4.3. OREGON GRAPE

11.4.4.3.1. MARKET VALUE (USD MN)

11.4.4.3.2. MARKET VOLUME (IU)

11.4.4.3.3. AVERAGE SELLING PRICE (USD)

11.5 PUSTULAR PSORIASIS

11.5.1 MEDICATION

11.5.1.1. CORTICOSTEROIDS

11.5.1.1.1. HYDROCORTISONE, BY BRAND

11.5.1.1.1.1 HYDROCORT

11.5.1.1.1.1.1. MARKET VALUE (USD MN)

11.5.1.1.1.1.2. MARKET VOLUME (IU)

11.5.1.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.1.2 ALPHOSYL

11.5.1.1.1.2.1. MARKET VALUE (USD MN)

11.5.1.1.1.2.2. MARKET VOLUME (IU)

11.5.1.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.1.3 AQUACORT

11.5.1.1.1.3.1. MARKET VALUE (USD MN)

11.5.1.1.1.3.2. MARKET VOLUME (IU)

11.5.1.1.1.3.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.1.4 OTHERS

11.5.1.1.2. TRIAMCINOLONE, BY BRAND

11.5.1.1.2.1 KENALOG IV

11.5.1.1.2.1.1. MARKET VALUE (USD MN)

11.5.1.1.2.1.2. MARKET VOLUME (IU)

11.5.1.1.2.1.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.2.2 ARISTOSPAN

11.5.1.1.2.2.1. MARKET VALUE (USD MN)

11.5.1.1.2.2.2. MARKET VOLUME (IU)

11.5.1.1.2.2.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.2.3 TRIVARIS

11.5.1.1.2.3.1. MARKET VALUE (USD MN)

11.5.1.1.2.3.2. MARKET VOLUME (IU)

11.5.1.1.2.3.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.2.4 OTHERS

 

11.5.1.1.3. CLOBETASOL, BY BRAND

11.5.1.1.3.1 TEMOVATE

11.5.1.1.3.1.1. MARKET VALUE (USD MN)

11.5.1.1.3.1.2. MARKET VOLUME (IU)

11.5.1.1.3.1.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.3.2 CLOBEX

11.5.1.1.3.2.1. MARKET VALUE (USD MN)

11.5.1.1.3.2.2. MARKET VOLUME (IU)

11.5.1.1.3.2.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.3.3 OLUX

11.5.1.1.3.3.1. MARKET VALUE (USD MN)

11.5.1.1.3.3.2. MARKET VOLUME (IU)

11.5.1.1.3.3.3. AVERAGE SELLING PRICE (USD)

11.5.1.1.3.4 OTHERS

11.5.1.2. CALCINEURIN INHIBITORS

11.5.1.2.1. TACROLIMUS, BY BRAND

11.5.1.2.1.1 PROGRAF

11.5.1.2.1.1.1. MARKET VALUE (USD MN)

11.5.1.2.1.1.2. MARKET VOLUME (IU)

11.5.1.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.5.1.2.1.2 ENVARSUS XR

11.5.1.2.1.2.1. MARKET VALUE (USD MN)

11.5.1.2.1.2.2. MARKET VOLUME (IU)

11.5.1.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.5.1.2.1.3 ASTAGRAF XL

11.5.1.2.1.3.1. MARKET VALUE (USD MN)

11.5.1.2.1.3.2. MARKET VOLUME (IU)

11.5.1.2.1.3.3. AVERAGE SELLING PRICE (USD)

11.5.1.2.1.4 OTHERS

11.5.1.2.2. PIMECROLIMUS (ELIDEL)

11.5.1.2.2.1.1. MARKET VALUE (USD MN)

11.5.1.2.2.1.2. MARKET VOLUME (IU)

11.5.1.2.2.1.3. AVERAGE SELLING PRICE (USD)

 

11.5.1.3. IMMUNOSUPPRESSANT

11.5.1.3.1. CYCLOSPORINE, BY BRAND NAME

11.5.1.3.1.1 SANDMMUNE

11.5.1.3.1.1.1. MARKET VALUE (USD MN)

11.5.1.3.1.1.2. MARKET VOLUME (IU)

11.5.1.3.1.1.3. AVERAGE SELLING PRICE (USD)

11.5.1.3.1.2 NEORAL

11.5.1.3.1.2.1. MARKET VALUE (USD MN)

11.5.1.3.1.2.2. MARKET VOLUME (IU)

11.5.1.3.1.2.3. AVERAGE SELLING PRICE (USD)

11.5.1.3.1.3 RESTASIS

11.5.1.3.1.3.1. MARKET VALUE (USD MN)

11.5.1.3.1.3.2. MARKET VOLUME (IU)

11.5.1.3.1.3.3. AVERAGE SELLING PRICE (USD)

11.5.1.3.1.4 OTHERS

11.5.1.3.2. METHOTREXATE, BY BRAND NAME

11.5.1.3.2.1 TREXALL

11.5.1.3.2.1.1. MARKET VALUE (USD MN)

11.5.1.3.2.1.2. MARKET VOLUME (IU)

11.5.1.3.2.1.3. AVERAGE SELLING PRICE (USD)

11.5.1.3.2.2 OTREXUP

11.5.1.3.2.2.1. MARKET VALUE (USD MN)

11.5.1.3.2.2.2. MARKET VOLUME (IU)

11.5.1.3.2.2.3. AVERAGE SELLING PRICE (USD)

11.5.1.3.2.3 RASUVO

11.5.1.3.2.3.1. MARKET VALUE (USD MN)

11.5.1.3.2.3.2. MARKET VOLUME (IU)

11.5.1.3.2.3.3. AVERAGE SELLING PRICE (USD)

11.5.1.3.2.4 OTHERS

11.5.1.3.3. BIOLOGIC DRUGS

11.5.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS

11.5.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.5.1.3.3.1.2. ETANERCEPT, BY BRAND NAME

A. ENBREL

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. ERELZI

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTHERS

11.5.1.3.3.1.3. ADALIMUMAB, BY BRAND

A. HUMIRA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. AMGEVITA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. HYRIMOZ

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

D. OTHERS

11.5.1.3.3.1.4. INFLIXIMAB, BY BRAND

A. REMICADE

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. RENFLEXIS

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTERS

11.5.1.3.3.1.5. GOLIMUMAB, (SIMPONI)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.5.1.3.3.1.6. OTHERS

11.5.1.3.3.2 INTERLEUKIN

11.5.1.3.3.2.1. USTEKINUMAB (STELARA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.5.1.3.3.2.2. SECUKINUMAB (COSENTYX)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.5.1.3.3.2.3. GUSELKUMAB (TREMFYA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.5.1.3.3.2.4. OTHERS

11.5.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.5.1.3.4. OTHERS

11.5.2 TOPICAL THERAPY

11.5.2.1. VITAMIN D

11.5.2.1.1. CALCIPOTRIENE,BY BRAND

11.5.2.1.1.1 DOVONEX

11.5.2.1.1.1.1. MARKET VALUE (USD MN)

11.5.2.1.1.1.2. MARKET VOLUME (IU)

11.5.2.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.5.2.1.1.2 SORILUX

11.5.2.1.1.2.1. MARKET VALUE (USD MN)

11.5.2.1.1.2.2. MARKET VOLUME (IU)

11.5.2.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.5.2.1.1.3 OTHERS

11.5.2.1.2. CALCITRIOL (VECTICAL)

11.5.2.1.2.1 MARKET VALUE (USD MN)

11.5.2.1.2.2 MARKET VOLUME (IU)

11.5.2.1.2.3 AVERAGE SELLING PRICE (USD)

 

11.5.2.2. RETINOIDS (TAZAROTENE), BY BRAND

11.5.2.2.1. TAZORAC

11.5.2.2.1.1 MARKET VALUE (USD MN)

11.5.2.2.1.2 MARKET VOLUME (IU)

11.5.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.5.2.2.2. AVAGE

11.5.2.2.2.1 MARKET VALUE (USD MN)

11.5.2.2.2.2 MARKET VOLUME (IU)

11.5.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.5.2.2.3. OTHERS

11.5.2.3. ANTHRALIN

11.5.2.3.1. MARKET VALUE (USD MN)

11.5.2.3.2. MARKET VOLUME (IU)

11.5.2.3.3. AVERAGE SELLING PRICE (USD)

11.5.2.4. SALICYLIC ACID

11.5.2.4.1. MARKET VALUE (USD MN)

11.5.2.4.2. MARKET VOLUME (IU)

11.5.2.4.3. AVERAGE SELLING PRICE (USD)

11.5.2.5. COAL TAR

11.5.2.5.1. MARKET VALUE (USD MN)

11.5.2.5.2. MARKET VOLUME (IU)

11.5.2.5.3. AVERAGE SELLING PRICE (USD)

11.5.2.6. OTHERS

11.5.3 LIGHT THERAPY

11.5.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)

11.5.3.2. UV B

11.5.3.2.1. BROAD BAND

11.5.3.2.2. NARROW BAND

11.5.3.3. EXCIMER LASER

11.5.4 SYMPTOMATIC MEDICINE

11.5.4.1. ALOE EXTRACT CREAM

11.5.4.1.1. MARKET VALUE (USD MN)

11.5.4.1.2. MARKET VOLUME (IU)

11.5.4.1.3. AVERAGE SELLING PRICE (USD)

11.5.4.2. FISH OIL SUPPLEMENTS

11.5.4.2.1. MARKET VALUE (USD MN)

11.5.4.2.2. MARKET VOLUME (IU)

11.5.4.2.3. AVERAGE SELLING PRICE (USD)

 

11.5.4.3. OREGON GRAPE

11.5.4.3.1. MARKET VALUE (USD MN)

11.5.4.3.2. MARKET VOLUME (IU)

11.5.4.3.3. AVERAGE SELLING PRICE (USD)

11.6 ERYTHRODERMIC PSORIASIS

11.6.1 MEDICATION

11.6.1.1. CORTICOSTEROIDS

11.6.1.1.1. HYDROCORTISONE, BY BRAND

11.6.1.1.1.1 HYDROCORT

11.6.1.1.1.1.1. MARKET VALUE (USD MN)

11.6.1.1.1.1.2. MARKET VOLUME (IU)

11.6.1.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.1.2 ALPHOSYL

11.6.1.1.1.2.1. MARKET VALUE (USD MN)

11.6.1.1.1.2.2. MARKET VOLUME (IU)

11.6.1.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.1.3 AQUACORT

11.6.1.1.1.3.1. MARKET VALUE (USD MN)

11.6.1.1.1.3.2. MARKET VOLUME (IU)

11.6.1.1.1.3.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.1.4 OTHERS

11.6.1.1.2. TRIAMCINOLONE, BY BRAND

11.6.1.1.2.1 KENALOG IV

11.6.1.1.2.1.1. MARKET VALUE (USD MN)

11.6.1.1.2.1.2. MARKET VOLUME (IU)

11.6.1.1.2.1.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.2.2 ARISTOSPAN

11.6.1.1.2.2.1. MARKET VALUE (USD MN)

11.6.1.1.2.2.2. MARKET VOLUME (IU)

11.6.1.1.2.2.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.2.3 TRIVARIS

11.6.1.1.2.3.1. MARKET VALUE (USD MN)

11.6.1.1.2.3.2. MARKET VOLUME (IU)

11.6.1.1.2.3.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.2.4 OTHERS

 

11.6.1.1.3. CLOBETASOL, BY BRAND

11.6.1.1.3.1 TEMOVATE

11.6.1.1.3.1.1. MARKET VALUE (USD MN)

11.6.1.1.3.1.2. MARKET VOLUME (IU)

11.6.1.1.3.1.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.3.2 CLOBEX

11.6.1.1.3.2.1. MARKET VALUE (USD MN)

11.6.1.1.3.2.2. MARKET VOLUME (IU)

11.6.1.1.3.2.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.3.3 OLUX

11.6.1.1.3.3.1. MARKET VALUE (USD MN)

11.6.1.1.3.3.2. MARKET VOLUME (IU)

11.6.1.1.3.3.3. AVERAGE SELLING PRICE (USD)

11.6.1.1.3.4 OTHERS

11.6.1.2. CALCINEURIN INHIBITORS

11.6.1.2.1. TACROLIMUS, BY BRAND

11.6.1.2.1.1 PROGRAF

11.6.1.2.1.1.1. MARKET VALUE (USD MN)

11.6.1.2.1.1.2. MARKET VOLUME (IU)

11.6.1.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.6.1.2.1.2 ENVARSUS XR

11.6.1.2.1.2.1. MARKET VALUE (USD MN)

11.6.1.2.1.2.2. MARKET VOLUME (IU)

11.6.1.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.6.1.2.1.3 ASTAGRAF XL

11.6.1.2.1.3.1. MARKET VALUE (USD MN)

11.6.1.2.1.3.2. MARKET VOLUME (IU)

11.6.1.2.1.3.3. AVERAGE SELLING PRICE (USD)

11.6.1.2.1.4 OTHERS

11.6.1.2.2. PIMECROLIMUS (ELIDEL)

11.6.1.2.2.1.1. MARKET VALUE (USD MN)

11.6.1.2.2.1.2. MARKET VOLUME (IU)

11.6.1.2.2.1.3. AVERAGE SELLING PRICE (USD)

 

11.6.1.3. IMMUNOSUPPRESSANT

11.6.1.3.1. CYCLOSPORINE, BY BRAND NAME

11.6.1.3.1.1 SANDMMUNE

11.6.1.3.1.1.1. MARKET VALUE (USD MN)

11.6.1.3.1.1.2. MARKET VOLUME (IU)

11.6.1.3.1.1.3. AVERAGE SELLING PRICE (USD)

11.6.1.3.1.2 NEORAL

11.6.1.3.1.2.1. MARKET VALUE (USD MN)

11.6.1.3.1.2.2. MARKET VOLUME (IU)

11.6.1.3.1.2.3. AVERAGE SELLING PRICE (USD)

11.6.1.3.1.3 RESTASIS

11.6.1.3.1.3.1. MARKET VALUE (USD MN)

11.6.1.3.1.3.2. MARKET VOLUME (IU)

11.6.1.3.1.3.3. AVERAGE SELLING PRICE (USD)

11.6.1.3.1.4 OTHERS

11.6.1.3.2. METHOTREXATE, BY BRAND NAME

11.6.1.3.2.1 TREXALL

11.6.1.3.2.1.1. MARKET VALUE (USD MN)

11.6.1.3.2.1.2. MARKET VOLUME (IU)

11.6.1.3.2.1.3. AVERAGE SELLING PRICE (USD)

11.6.1.3.2.2 OTREXUP

11.6.1.3.2.2.1. MARKET VALUE (USD MN)

11.6.1.3.2.2.2. MARKET VOLUME (IU)

11.6.1.3.2.2.3. AVERAGE SELLING PRICE (USD)

11.6.1.3.2.3 RASUVO

11.6.1.3.2.3.1. MARKET VALUE (USD MN)

11.6.1.3.2.3.2. MARKET VOLUME (IU)

11.6.1.3.2.3.3. AVERAGE SELLING PRICE (USD)

11.6.1.3.2.4 OTHERS

11.6.1.3.3. BIOLOGIC DRUGS

11.6.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS

11.6.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.6.1.3.3.1.2. ETANERCEPT, BY BRAND NAME

A. ENBREL

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. ERELZI

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTHERS

11.6.1.3.3.1.3. ADALIMUMAB, BY BRAND

A. HUMIRA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. AMGEVITA

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. HYRIMOZ

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

D. OTHERS

11.6.1.3.3.1.4. INFLIXIMAB, BY BRAND

A. REMICADE

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

B. RENFLEXIS

I. MARKET VALUE (USD MN)

II. MARKET VOLUME (IU)

III. AVERAGE SELLING PRICE (USD)

C. OTERS

11.6.1.3.3.1.5. GOLIMUMAB, (SIMPONI)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.6.1.3.3.1.6. OTHERS

11.6.1.3.3.2 INTERLEUKIN

11.6.1.3.3.2.1. USTEKINUMAB (STELARA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.6.1.3.3.2.2. SECUKINUMAB (COSENTYX)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.6.1.3.3.2.3. GUSELKUMAB (TREMFYA)

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.6.1.3.3.2.4. OTHERS

11.6.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT

A. MARKET VALUE (USD MN)

B. MARKET VOLUME (IU)

C. AVERAGE SELLING PRICE (USD)

11.6.1.3.4. OTHERS

11.6.2 TOPICAL THERAPY

11.6.2.1. VITAMIN D

11.6.2.1.1. CALCIPOTRIENE,BY BRAND

11.6.2.1.1.1 DOVONEX

11.6.2.1.1.1.1. MARKET VALUE (USD MN)

11.6.2.1.1.1.2. MARKET VOLUME (IU)

11.6.2.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.6.2.1.1.2 SORILUX

11.6.2.1.1.2.1. MARKET VALUE (USD MN)

11.6.2.1.1.2.2. MARKET VOLUME (IU)

11.6.2.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.6.2.1.1.3 OTHERS

11.6.2.1.2. CALCITRIOL (VECTICAL)

11.6.2.1.2.1 MARKET VALUE (USD MN)

11.6.2.1.2.2 MARKET VOLUME (IU)

11.6.2.1.2.3 AVERAGE SELLING PRICE (USD)

 

11.6.2.2. RETINOIDS (TAZAROTENE), BY BRAND

11.6.2.2.1. TAZORAC

11.6.2.2.1.1 MARKET VALUE (USD MN)

11.6.2.2.1.2 MARKET VOLUME (IU)

11.6.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.2. AVAGE

11.6.2.2.2.1 MARKET VALUE (USD MN)

11.6.2.2.2.2 MARKET VOLUME (IU)

11.6.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.6.2.2.3. OTHERS

11.6.2.3. ANTHRALIN

11.6.2.3.1. MARKET VALUE (USD MN)

11.6.2.3.2. MARKET VOLUME (IU)

11.6.2.3.3. AVERAGE SELLING PRICE (USD)

11.6.2.4. SALICYLIC ACID

11.6.2.4.1. MARKET VALUE (USD MN)

11.6.2.4.2. MARKET VOLUME (IU)

11.6.2.4.3. AVERAGE SELLING PRICE (USD)

11.6.2.5. COAL TAR

11.6.2.5.1. MARKET VALUE (USD MN)

11.6.2.5.2. MARKET VOLUME (IU)

11.6.2.5.3. AVERAGE SELLING PRICE (USD)

11.6.2.6. OTHERS

11.6.3 LIGHT THERAPY

11.6.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)

11.6.3.2. UV B

11.6.3.2.1. BROAD BAND

11.6.3.2.2. NARROW BAND

11.6.3.3. EXCIMER LASER

11.6.4 SYMPTOMATIC MEDICINE

11.6.4.1. ALOE EXTRACT CREAM

11.6.4.1.1. MARKET VALUE (USD MN)

11.6.4.1.2. MARKET VOLUME (IU)

11.6.4.1.3. AVERAGE SELLING PRICE (USD)

11.6.4.2. FISH OIL SUPPLEMENTS

11.6.4.2.1. MARKET VALUE (USD MN)

11.6.4.2.2. MARKET VOLUME (IU)

11.6.4.2.3. AVERAGE SELLING PRICE (USD)

 

11.6.4.3. OREGON GRAPE

11.6.4.3.1. MARKET VALUE (USD MN)

11.6.4.3.2. MARKET VOLUME (IU)

11.6.4.3.3. AVERAGE SELLING PRICE (USD)

12 GLOBAL PSORIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 ORAL

12.2.1 TABLETS

12.2.2 PILLS

12.2.3 OTHERS

12.3 PARENTERAL

12.3.1 INTRAVENOUS

12.3.2 SUBCUTANEOUS

12.3.3 OTHERS

12.4 TOPICAL

12.4.1 GEL

12.4.2 CREAM

12.4.3 FOAM

12.4.4 OINTMENTS

12.4.5 SPRAY

12.4.6 SHAMPOO

12.4.7 LOTION

12.4.8 OTHERS

13 GLOBAL PSORIASIS TREATMENT MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 THERAPY CENTERS

13.6 OTHERS

14 GLOBAL PSORIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 HOSPITAL PHARMACY

14.4 RETAIL PHARMACY

14.5 ONLINE PHARMACY

14.6 OTHERS

15 GLOBAL PSORIASIS TREATMENT MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15.5 MERGERS & ACQUISITIONS

15.6 NEW PRODUCT DEVELOPMENT & APPROVALS

15.7 EXPANSIONS

15.8 REGULATORY CHANGES

15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

16 GLOBAL PSORIASIS TREATMENT MARKET, BY GEOGRAPHY

16.1 GLOBAL PSORIASIS TREATMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

16.2 NORTH AMERICA

16.2.1 U.S.

16.2.1.1. U.S. PSORIASIS TREATMENT MARKET, BY TYPE

16.2.1.2. U.S. PSORIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

16.2.1.3. U.S. PSORIASIS TREATMENT MARKET, BY END USER

16.2.1.4. U.S. PSORIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

16.3 CANADA

16.3.1 MEXICO

16.3.2 DOMINICAN REPUBLIC

16.3.3 JAMAICA

16.3.4 PANAMA

 

16.4 EUROPE

16.4.1 GERMANY

16.4.2 FRANCE

16.4.3 U.K.

16.4.4 HUNGARY

16.4.5 LITHUANIA

16.4.6 AUSTRIA

16.4.7 IRELAND

16.4.8 NORWAY

16.4.9 POLAND

16.4.10 ITALY

16.4.11 SPAIN

16.4.12 RUSSIA

16.4.13 TURKEY

16.4.14 NETHERLANDS

16.4.15 SWITZERLAND

16.4.16 REST OF EUROPE

16.5 ASIA-PACIFIC

16.5.1 JAPAN

16.5.2 CHINA

16.5.3 TAIWAN

16.5.4 SOUTH KOREA

16.5.5 INDIA

16.5.6 AUSTRALIA

16.5.7 SINGAPORE

16.5.8 THAILAND

16.5.9 MALAYSIA

16.5.10 INDONESIA

16.5.11 PHILIPPINES

16.5.12 VIETNAM

16.5.13 REST OF ASIA-PACIFIC

 

16.6 SOUTH AMERICA

16.6.1 BRAZIL

16.6.2 ECUADOR

16.6.3 CHILE

16.6.4 COLOMBIA

16.6.5 VENEZUELA

16.6.6 ARGENTINA

16.6.7 PERU

16.6.8 CURAÇAO

16.6.9 PARAGUAY

16.6.10 URUGUAY

16.6.11 TRINIDAD AND TOBAGO

16.6.12 REST OF SOUTH AMERICA

16.7 MIDDLE EAST AND AFRICA

16.7.1 SOUTH AFRICA

16.7.2 SAUDI ARABIA

16.7.3 UAE

16.7.4 EGYPT

16.7.5 KUWAIT

16.7.6 ISRAEL

16.7.7 BOLIVIA

16.7.8 REST OF MIDDLE EAST AND AFRICA

16.7.9 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

17 GLOBAL PSORIASIS TREATMENT MARKET, SWOT AND DBMR ANALYSIS

18 GLOBAL PSORIASIS TREATMENT MARKET, COMPANY PROFILE

18.1 PERRIGO COMPANY PLC

18.1.1 COMPANY OVERVIEW

18.1.2 REVENUE ANALYSIS

18.1.3 GEOGRAPHIC PRESENCE

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 SANOFI

18.2.1 COMPANY OVERVIEW

18.2.2 REVENUE ANALYSIS

18.2.3 GEOGRAPHIC PRESENCE

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

 

18.3 GLAXOSMITHKLINE

18.3.1 COMPANY OVERVIEW

18.3.2 REVENUE ANALYSIS

18.3.3 GEOGRAPHIC PRESENCE

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 MERCK & CO, INC

18.4.1 COMPANY OVERVIEW

18.4.2 REVENUE ANALYSIS

18.4.3 GEOGRAPHIC PRESENCE

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 F-HOFFMANN LA ROCHE

18.5.1 COMPANY OVERVIEW

18.5.2 REVENUE ANALYSIS

18.5.3 GEOGRAPHIC PRESENCE

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENTS

18.6 PFIZER

18.6.1 COMPANY OVERVIEW

18.6.2 REVENUE ANALYSIS

18.6.3 GEOGRAPHIC PRESENCE

18.6.4 PRODUCT PORTFOLIO

18.6.5 RECENT DEVELOPMENTS

18.7 JOHNSON & JOHNSON

18.7.1 COMPANY OVERVIEW

18.7.2 REVENUE ANALYSIS

18.7.3 GEOGRAPHIC PRESENCE

18.7.4 PRODUCT PORTFOLIO

18.7.5 RECENT DEVELOPMENTS

18.8 COSETTE PHARMACEUTICALS, INC.

18.8.1 COMPANY OVERVIEW

18.8.2 REVENUE ANALYSIS

18.8.3 GEOGRAPHIC PRESENCE

18.8.4 PRODUCT PORTFOLIO

18.8.5 RECENT DEVELOPMENTS

 

18.9 LUPIN

18.9.1 COMPANY OVERVIEW

18.9.2 REVENUE ANALYSIS

18.9.3 GEOGRAPHIC PRESENCE

18.9.4 PRODUCT PORTFOLIO

18.9.5 RECENT DEVELOPMENTS

18.9.6 MYLAN N.V.

18.9.7 COMPANY OVERVIEW

18.9.8 REVENUE ANALYSIS

18.9.9 GEOGRAPHIC PRESENCE

18.9.10 PRODUCT PORTFOLIO

18.9.11 RECENT DEVELOPMENTS

18.1 WOCKHARDT

18.10.1 COMPANY OVERVIEW

18.10.2 REVENUE ANALYSIS

18.10.3 GEOGRAPHIC PRESENCE

18.10.4 PRODUCT PORTFOLIO

18.10.5 RECENT DEVELOPMENTS

18.11 TOLMAR PHARMACEUTICALS, INC.

18.11.1 COMPANY OVERVIEW

18.11.2 REVENUE ANALYSIS

18.11.3 GEOGRAPHIC PRESENCE

18.11.4 PRODUCT PORTFOLIO

18.11.5 RECENT DEVELOPMENTS

18.12 AKORN, INCORPORATED

18.12.1 COMPANY OVERVIEW

18.12.2 REVENUE ANALYSIS

18.12.3 GEOGRAPHIC PRESENCE

18.12.4 PRODUCT PORTFOLIO

18.12.5 RECENT DEVELOPMENTS

18.13 TELIGENT

18.13.1 COMPANY OVERVIEW

18.13.2 REVENUE ANALYSIS

18.13.3 GEOGRAPHIC PRESENCE

18.13.4 PRODUCT PORTFOLIO

18.13.5 RECENT DEVELOPMENTS

 

18.14 GLENMARK PHARMACEUTICAL INC.

18.14.1 COMPANY OVERVIEW

18.14.2 REVENUE ANALYSIS

18.14.3 GEOGRAPHIC PRESENCE

18.14.4 PRODUCT PORTFOLIO

18.14.5 RECENT DEVELOPMENTS

18.15 XIROMED

18.15.1 COMPANY OVERVIEW

18.15.2 REVENUE ANALYSIS

18.15.3 GEOGRAPHIC PRESENCE

18.15.4 PRODUCT PORTFOLIO

18.15.5 RECENT DEVELOPMENTS

18.16 AMNEAL PHARMACEUTICALS LLC

18.16.1 COMPANY OVERVIEW

18.16.2 REVENUE ANALYSIS

18.16.3 GEOGRAPHIC PRESENCE

18.16.4 PRODUCT PORTFOLIO

18.16.5 RECENT DEVELOPMENTS

18.17 ENCUBE ETHICALS

18.17.1 COMPANY OVERVIEW

18.17.2 REVENUE ANALYSIS

18.17.3 GEOGRAPHIC PRESENCE

18.17.4 PRODUCT PORTFOLIO

18.17.5 RECENT DEVELOPMENTS

18.18 INGENUS PHARMACEUTICALS, LLC

18.18.1 COMPANY OVERVIEW

18.18.2 REVENUE ANALYSIS

18.18.3 GEOGRAPHIC PRESENCE

18.18.4 PRODUCT PORTFOLIO

18.18.5 RECENT DEVELOPMENTS

18.19 ALEOR DERMACEUTICALS LIMITED

18.19.1 COMPANY OVERVIEW

18.19.2 REVENUE ANALYSIS

18.19.3 GEOGRAPHIC PRESENCE

18.19.4 PRODUCT PORTFOLIO

18.19.5 RECENT DEVELOPMENTS

 

18.2 SANDOZ AG

18.20.1 COMPANY OVERVIEW

18.20.2 REVENUE ANALYSIS

18.20.3 GEOGRAPHIC PRESENCE

18.20.4 PRODUCT PORTFOLIO

18.20.5 RECENT DEVELOPMENTS

18.21 ENCORE DERMATOLOGY, INC.,

18.21.1 COMPANY OVERVIEW

18.21.2 REVENUE ANALYSIS

18.21.3 GEOGRAPHIC PRESENCE

18.21.4 PRODUCT PORTFOLIO

18.21.5 RECENT DEVELOPMENTS

18.22 ZYDUS PHARMACEUTICALS, INC.

18.22.1 COMPANY OVERVIEW

18.22.2 REVENUE ANALYSIS

18.22.3 GEOGRAPHIC PRESENCE

18.22.4 PRODUCT PORTFOLIO

18.22.5 RECENT DEVELOPMENTS

18.23 TEVA PHARMACEUTICALS USA, INC.

18.23.1 COMPANY OVERVIEW

18.23.2 REVENUE ANALYSIS

18.23.3 GEOGRAPHIC PRESENCE

18.23.4 PRODUCT PORTFOLIO

18.23.5 RECENT DEVELOPMENTS

18.24 STIEFEL LABORATORIES, INC.

18.24.1 COMPANY OVERVIEW

18.24.2 REVENUE ANALYSIS

18.24.3 GEOGRAPHIC PRESENCE

18.24.4 PRODUCT PORTFOLIO

18.24.5 RECENT DEVELOPMENTS

18.25 SIGMAPHARM LABORATORIES, LLC.

18.25.1 COMPANY OVERVIEW

18.25.2 REVENUE ANALYSIS

18.25.3 GEOGRAPHIC PRESENCE

18.25.4 PRODUCT PORTFOLIO

18.25.5 RECENT DEVELOPMENTS

 

18.26 THE DAAVLIN COMPANY

18.26.1 COMPANY OVERVIEW

18.26.2 REVENUE ANALYSIS

18.26.3 GEOGRAPHIC PRESENCE

18.26.4 PRODUCT PORTFOLIO

*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

19 RELATED REPORTS

20 CONCLUSION

21 QUESTIONNAIRE

22 ABOUT DATA BRIDGE MARKET RESEARCH